Evidence map›Paper›PMID 42903198›Full record

ReviewThe Lancet regional health. Southeast Asia2026

Thalassaemia prevention in Asia: progress, challenges, and future directions.

Michael Angastiniotis, Suthat Fucharoen, Kittiphong Paiboonsukwong, Ha Thanh Nguyen, Thi Thu Ha Nguyen, Hai Yang Law, Pustika Amalia Wahidiyat, Sourideth Sengchanh, Norehan Johari, Chean Sophâl and 4 more

Abstract readReview
In one paragraph

Review in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Michael AngastiniotisThalassaemia International Federation, Nicosia, Cyprus.
Suthat FucharoenThalassemia Research Center, Institute of Molecular Biosciences, Mahidol University and Samitvej Srinakarin Hospital, Bangkok, Thailand.
Kittiphong PaiboonsukwongThalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.
Ha Thanh NguyenNational Institute of Haematology and Blood Transfusion and Hanoi Medical University, Hanoi, Viet Nam.
Thi Thu Ha NguyenThalassemia Centre, National Institute of Haematology and Blood Transfusion, Hanoi, Viet Nam.
Hai Yang LawNational Thalassemia Registry, Department of Genomic Medicine, KK Women's and Children's Hospital, Singapore.
Pustika Amalia WahidiyatPediatric Hematology-Oncology Division, Department of Child Health, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Sourideth SengchanhDepartment of Paediatrics, University of Health Sciences, Vientiane, Laos.
Norehan JohariDepartment of Pediatrics, Raja Isteri Pengiran Anak Saleha Hospital, Bandar Seri Begawan, Brunei Darussalam.
Chean SophâlDepartment of Pediatric Hematology - Immunology and Transfusion Medicine, National Pediatric Hospital, University of Health Sciences, Phnom Penh, Cambodia.
Maria Liza T NaranjoThalassemia Action Network, Philippine Society of Hematology and Blood Transfusion, Blood and Cancer Care Center, National Children's Hospital, Manila, Philippines.
Nita RadhakrishnanDepartment of Pediatric Hematology Oncology, Post Graduate Institute of Child Health (PGICH), Delhi NCR, Noida, India.
Khaled M MusallamCenter for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
Androulla EleftheriouThalassaemia International Federation, Nicosia, Cyprus.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thalassaemia remains a major public health burden in Asia, where high carrier frequencies, diverse mutation spectra, and variable healthcare capacity continue to influence disease prevention and control. This Series paper summarises the status of thalassaemia prevention programmes across 14 Asian countries and highlights the key challenges and opportunities affecting their implementation. Singapore, Malaysia, the Maldives, and Thailand have established the most structured prevention strategies, incorporating combinations of public awareness, carrier screening, genetic counselling, and prenatal diagnosis, with measurable success most clearly demonstrated in Singapore and, to a specific extent, Thailand. In contrast, many other countries in the region continue to face fragmented services, limited national coordination, shortages of trained personnel, inadequate epidemiological data, and financial, technological, cultural, and social barriers. Differences in prevention efforts broadly reflect wider disparities in health system development. Strengthening national prevention programmes should be viewed as both a public health priority and a cost-effective investment in reducing long-term disease burden.

Indexed as

CarrierControlDiagnosisEpidemiologyPreventionScreening

Identifiers

PMID42903198
PMCPMC13680628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.